These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36064940)

  • 1. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
    Reincke M; Schultheiss M; Doppler M; Verloh N; Uller W; Sturm L; Thimme R; Goetz C; Bettinger D
    Hepatol Commun; 2022 Nov; 6(11):3223-3233. PubMed ID: 36064940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization.
    Gelardi F; Rodari M; Pini C; Zanca R; Artesani A; Tosi G; Chiti A; Sollini M
    Front Nucl Med; 2022; 2():934446. PubMed ID: 39354974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Mohammed MAA; Khalaf MH; Liang T; Wang DS; Lungren MP; Rosenberg J; Kothary N
    J Vasc Interv Radiol; 2018 Nov; 29(11):1527-1534.e1. PubMed ID: 30274856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study.
    Carrión L; Clemente-Sánchez A; Márquez-Pérez L; Orcajo-Rincón J; Rotger A; Ramón-Botella E; González-Leyte M; Echenagusía-Boyra M; Luis Colón A; Reguera-Berenguer L; Bañares R; Rincón D; Matilla-Peña A
    Therap Adv Gastroenterol; 2023; 16():17562848231206995. PubMed ID: 37920686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.
    Navadurong H; Thanapirom K; Wejnaruemarn S; Prasoppokakorn T; Chaiteerakij R; Komolmit P; Treeprasertsuk S
    World J Gastroenterol; 2023 Aug; 29(32):4873-4882. PubMed ID: 37701131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumor: Transarterial Chemoembolization versus Transarterial Radioembolization.
    Currie BM; Nadolski G; Mondschein J; Dagli M; Sudheendra D; Stavropoulos SW; Soulen MC
    J Vasc Interv Radiol; 2020 Oct; 31(10):1627-1635. PubMed ID: 33004146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
    Pinato DJ; Sharma R; Allara E; Yen C; Arizumi T; Kubota K; Bettinger D; Jang JW; Smirne C; Kim YW; Kudo M; Howell J; Ramaswami R; Burlone ME; Guerra V; Thimme R; Ishizuka M; Stebbing J; Pirisi M; Carr BI
    J Hepatol; 2017 Feb; 66(2):338-346. PubMed ID: 27677714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
    Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
    Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study.
    Bayona Molano MDP; Kolber M; Barrera JV; Akram MR; Alnablsi MW; Pothini T; Salem R; Singal AG
    Cureus; 2024 Jun; 16(6):e61904. PubMed ID: 38855496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioembolization of hepatocarcinoma with
    Chiesa C; Mira M; Bhoori S; Bormolini G; Maccauro M; Spreafico C; Cascella T; Cavallo A; De Nile MC; Mazzaglia S; Capozza A; Tagliabue G; Brusa A; Marchianò A; Seregni E; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.